1-4 of 4
Kimberly R. Jordan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

Robert W. Lentz, Tyler J. Friedrich, Patrick J. Blatchford, Kimberly R. Jordan, Todd M. Pitts, Hannah R. Robinson, S. Lindsey Davis, Sunnie S. Kim, Alexis D. Leal, Mathew R. Lee, Meredith R.N. Waring, Anne C. Martin, Adrian T.A. Dominguez, Stacey M. Bagby, Sarah J. Hartman, S. Gail Eckhardt, Wells A. Messersmith, Christopher H. Lieu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3768–3778.
https://doi.org/10.1158/1078-0432.CCR-24-0090
Published: 03 September 2024
View article titled, A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Open the PDF for A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Richard P. Tobin, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S.W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland, William A. Robinson, Martin D. McCarter
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1209–1219.
https://doi.org/10.1158/1078-0432.CCR-22-2495
Published: 03 April 2023
View article titled, Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Open the PDF for Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval

Kimberly R. Jordan, Matthew J. Sikora, Jill E. Slansky, Angela Minic, Jennifer K. Richer, Marisa R. Moroney, Junxiao Hu, Rebecca J. Wolsky, Zachary L. Watson, Tomomi M. Yamamoto, James C. Costello, Aaron Clauset, Kian Behbakht, T. Rajendra Kumar, Benjamin G. Bitler
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6362–6373.
https://doi.org/10.1158/1078-0432.CCR-20-1762
Published: 01 December 2020
View article titled, The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Open the PDF for The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval in another window
Includes: Supplementary data
Journal Articles

Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination

Shelby Lennon, Ayman Oweida, Dallin Milner, Andy V. Phan, Shilpa Bhatia, Benjamin Van Court, Laurel Darragh, Adam C. Mueller, David Raben, Jorge L. Martínez-Torrecuadrada, Todd M. Pitts, Hilary Somerset, Kimberly R. Jordan, Kirk C. Hansen, Jason Williams, Wells A. Messersmith, Richard D. Schulick, Philip Owens, Karyn A. Goodman, Sana D. Karam
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3352–3365.
https://doi.org/10.1158/1078-0432.CCR-18-2811
Published: 03 June 2019
View article titled, Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination
Open the PDF for Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination in another window
Includes: Supplementary data